Abstract
As pivotal practice-changing studies, the KEYNOTE-826 (KN826) and BEATcc trials provided the opportunity to add immune checkpoint inhibitors (ICPIs) to the combination of platinum-taxane doublet chemotherapy and bevacizumab, which has been the standard of care for advanced cervical cancer for many years. Combination with ICPI represents the current benchmark for the first-line treatment of advanced cervical cancer. However, there are still issues that need to be questioned in terms of precision medicine. Studies that are not limited by the selection criteria of randomized clinical trials, reflect real-life practices, and measure outcomes for larger patient groups with more balanced representation of different subgroups would be valuable.
References
- Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734-743. doi:10.1056/NEJMoa1309748
- Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021;385(20):1856-1867. doi:10.1056/NEJMoa2112435
- Oaknin A, Gladieff L, Martínez-García J, et al. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet. 2024;403(10421):31-43. doi:10.1016/S0140-6736(23)02405-4
- Luo PH, Mo DC, Wang HL, Liang XJ, Huang JF. Predicted value of PD-L1 for patients with cervical cancer treated with pembrolizumab. J Clin Oncol. 2024;42(13):1596. doi:10.1200/JCO.23.02479
- Lichter KE, Levinson K, Hammer A, Lippitt MH, Rositch AF. Understanding cervical cancer after the age of routine screening: characteristics of cases, treatment, and survival in the United States. Gynecol Oncol. 2022;165(1):67-74. doi:10.1016/j.ygyno.2022.01.017
Abstract
Önemli uygulama değiştiren çalışmalar olarak, KEYNOTE-826 (KN826) ve BEATcc çalışmaları, uzun yıllardır ileri servikal kanser için bakım standardı olan platin-taksan dublet kemoterapisi ve bevacizumab kombinasyonuna bağışıklık kontrol noktası inhibitörleri (ICPI'ler) ekleme fırsatı sağladı. ICPI ile kombinasyon, ileri servikal kanserin birinci basamak tedavisi için artık optimal tedaviyi temsil etmektedir. Ancak, bireyselleştirilmiş kanser tedavisi açısından değerlendirilmeye açık noktalar vardır. Klinik çalışmaların seçim kriterleriyle sınırlı olmayan, gerçek yaşam uygulamalarını yansıtan ve farklı alt grupların daha dengeli bir temsiliyle daha büyük hasta grupları için sonuçları değerlendiren çalışmalar değerli olacaktır.
Ethical Statement
çalışmamızda editöre mektup niteliğinden dolayı etik kurul onayı alınmamıştır.
Supporting Institution
destekleyen kurum bulunmamaktadır
Thanks
yazımızın değerlendirilmesi için gösterilen emekten dolayı çok teşekkür ederiz.
References
- Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734-743. doi:10.1056/NEJMoa1309748
- Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021;385(20):1856-1867. doi:10.1056/NEJMoa2112435
- Oaknin A, Gladieff L, Martínez-García J, et al. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet. 2024;403(10421):31-43. doi:10.1016/S0140-6736(23)02405-4
- Luo PH, Mo DC, Wang HL, Liang XJ, Huang JF. Predicted value of PD-L1 for patients with cervical cancer treated with pembrolizumab. J Clin Oncol. 2024;42(13):1596. doi:10.1200/JCO.23.02479
- Lichter KE, Levinson K, Hammer A, Lippitt MH, Rositch AF. Understanding cervical cancer after the age of routine screening: characteristics of cases, treatment, and survival in the United States. Gynecol Oncol. 2022;165(1):67-74. doi:10.1016/j.ygyno.2022.01.017
Details
| Primary Language | English |
|---|---|
| Subjects | Clinical Oncology |
| Journal Section | Letter to the Editor |
| Authors | |
| Publication Date | May 30, 2025 |
| Submission Date | February 12, 2025 |
| Acceptance Date | April 20, 2025 |
| Published in Issue | Year 2025 Volume: 8 Issue: 3 |
Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS].
The Directories (indexes) and Platforms we are included in are at the bottom of the page.
Note: Our journal is not WOS indexed and therefore is not classified as Q.
You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/2316/file/4905/show
The indexes of the journal are ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, etc.
|
|
|
| |
|
|
|
|
The platforms of the journal are Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons, etc.
|
|
|
|
|
|
Our Journal using the DergiPark system indexed are;
Ulakbim TR Dizin, Index Copernicus, ICI World of Journals, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, OpenAIRE, MIAR, EuroPub, WorldCat (OCLC), DOAJ, Türkiye Citation Index, Türk Medline Index, InfoBase Index
Our Journal using the DergiPark system platforms are;
Journal articles are evaluated as "Double-Blind Peer Review".
Our journal has adopted the Open Access Policy and articles in JHSM are Open Access and fully comply with Open Access instructions. All articles in the system can be accessed and read without a journal user. https//dergipark.org.tr/tr/pub/jhsm/page/9535
Journal charge policy https://dergipark.org.tr/tr/pub/jhsm/page/10912
Our journal has been indexed in DOAJ as of May 18, 2020.
Our journal has been indexed in TR-Dizin as of March 12, 2021.
Articles published in the Journal of Health Sciences and Medicine have open access and are licensed under the Creative Commons CC BY-NC-ND 4.0 International License.